Pancreatic Disorders & Therapy
Open Access
ISSN: 2165-7092
+44 1478 350008
ISSN: 2165-7092
+44 1478 350008
Niu Zuo-xing
Shan Dong Tumor Hospital,
Jinan, 250117
Indiana
Review Article
Stage II Trial of Capecitabine Joined Together with Thalidomide in Second-Line Medicine of Progressed Pancreatic Growth
Author(s): Shi Sheng-bin, Wang Meng, Niu Zuo-xing, Tang Xiao-yong and Quan Yun-LiuShi Sheng-bin, Wang Meng, Niu Zuo-xing, Tang Xiao-yong and Quan Yun-Liu
Abstract Background: To assess the viability and averageness of capecitabine joined together with thalidomide in patients with propelled pancreatic disease (APC) who have beforehand accepted gemcitabine-based treatment. Systems: what added up to 31 patients were enrolled prospectively in Shandong Tumor Hospital from May 2007 to April 2009. Capecitabine was offered to patients twice a day at a dosage of 1,250 mg/m2 for 14-days then emulated by 7-day rest. Thalidomide was controlled 100 mg/day without interference until sickness movement or event of inadmissible poisonous quality. Results: Two patients put forth fractional reaction (PR), eleven patients indicated stable ailment (SD) and eighteen patients exhibited continuous illness (PD). The average without movement survival (PFS) was 2.7 months (95% expectancy interim (CI), 2.4-3.3) and the average generally speaking survival (OS) was.. View More»
DOI:
10.4172/2165-7092.1000109